ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.
Accretion Pharmaceuticals Limited has provided the web link for shareholders to access its Annual Report for FY 2025-26 and the 3rd AGM notice.
Accretion Pharmaceuticals Limited has scheduled its 3rd Annual General Meeting for August 27, 2026, to be conducted through video conferencing for ordinary business transactions.
Accretion Pharmaceuticals' HR Manager, Ms. Bandana Kumari, resigned effective 2nd July 2026. The resignation is for personal reasons, with no material issues reported.
Accretion Pharmaceuticals responded to exchange clarifications regarding financial results. The company provided an auditor's certificate confirming ₹27.75 Crore in IPO fund utilization.
Accretion Pharmaceuticals reported strong FY26 performance with ₹89.63 cr total income and 10.8% PAT margin, driven by export growth.
Accretion Pharmaceuticals approved the appointment of a new HR Manager and internal/secretarial auditors. These appointments strengthen the company's leadership and regulatory compliance frameworks.
Accretion Pharmaceuticals Ltd reported revenue from operations of ₹45.9 Cr (+18.3% YoY) and net profit of ₹4.9 Cr (+14.0% YoY) for H2 FY26.
Accretion Pharmaceuticals approved its FY26 audited financial results and appointed Ms. Bandana Kumari as HR Manager. Net profit for the period reached ₹9.67 Crore.
Accretion Pharmaceuticals Limited submitted its annual Structured Digital Database (SDD) compliance certificate for the financial year ended March 31, 2026. The certificate, issued by M/s. Sakhiya & Co., confirms that the company maintains a non-tamperable digital database for tracking UPSI events in accordance with SEBI Insider Trading Regulations.
Accretion Pharmaceuticals Limited has scheduled a Board Meeting for May 8, 2026, to consider and approve its audited standalone financial results for the year ended March 31, 2026. Consequently, the trading window for designated persons has been closed from April 1, 2026.
Accretion Pharmaceuticals Limited informed the National Stock Exchange that it does not fall under the 'Large Corporate' category for the financial year 2026–2027. Consequently, the specific disclosure and compliance requirements for debt security issuance by large entities under SEBI circulars are not applicable to the company.
Accretion Pharmaceuticals Limited informed the NSE that Regulation 27(2) regarding quarterly corporate governance reports is not applicable. As an SME-listed entity, the company is exempt under SEBI LODR Regulation 15(2)(b). A certificate from Sakhiya & Co confirms this non-applicability for the quarter ended March 31, 2026.
Accretion Pharmaceuticals Limited submitted its Regulation 74(5) compliance certificate for the quarter ended March 31, 2026. The certificate from RTA KFin Technologies confirms that all company shares are in dematerialized form and no rematerialization requests were received during the period.